Patient related factors affecting in-hospital costs of a TURP procedure.

Scand J Urol

Institute of Clinical Sciences at the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Published: August 2021

Treatment costs of lower urinary tract symptoms secondary to benign prostatic enlargement (BPE) are a substantial economic burden that will continue to increase in the future as a result of the ageing male population and increasing health awareness. The true costs for surgical interventions against BPE have been difficult to quantify as treatment costs strongly depend on the performance setting and may also vary among different healthcare systems, regions and institutions. The purpose of this study was to disclose the in-hospital costs and main expense items associated with a transurethral resection of the prostate (TURP). A cohort of men subjected to TURP due to BPE was analysed during a 3-year period (2017-2019). All in-hospital expenses were registered using an electronic spreadsheet. Patient background and perioperative variables were registered using retrospective chart reviews. A total of 122 men were available for final analysis. Of these, 70 men were operated on due to bothersome LUTS and 52 men due to urinary retention. The mean and median (inter quartile range) cost per patient was €4025 and €3702 (2961 - 4390), respectively. The main drivers of total cost were length of stay, the surgical procedure and anaesthesia related costs. Factors associated with increasing total cost per patient were increasing age, prostate volume, presence of urinary retention, occurrence of complications, increasing catheter time and length of stay. The main factor that influences total cost for an elective TURP procedure is the occurrence of postoperative complications. Our findings firmly underscore the indispensability to employ every possible means to avoid and prevent complications of any kind.

Download full-text PDF

Source
http://dx.doi.org/10.1080/21681805.2021.1893380DOI Listing

Publication Analysis

Top Keywords

total cost
12
in-hospital costs
8
turp procedure
8
treatment costs
8
urinary retention
8
cost patient
8
length stay
8
costs
6
patient
4
patient factors
4

Similar Publications

Background: Older adults and Hispanic individuals are increasingly turning to social media platforms to access health-related information. The purpose of this project was to evaluate a social media campaign to disseminate information from decision aids (DAs) on hip and knee osteoarthritis to Spanish-speaking adults.

Methods: A social media marketing team helped create an 8-mo campaign posted across 3 social media platforms to promote visits to a Web site offering free multilingual DAs for treatment of hip or knee osteoarthritis.

View Article and Find Full Text PDF

Introduction: This systematic review and meta-analysis aimed to systematically assess the effect size of conservative methods based on exercise for respondents with idiopathic scoliosis.

Methods: This study was developed in accordance with the PRISMA guidelines. The PubMed, Cochrane Library, Web of Science, and Google Scholar databases were searched in May 2023.

View Article and Find Full Text PDF

Introduction: Daratumumab is an anti-CD38 monoclonal antibody used in the treatment of myeloma and other related disorders. To mitigate the risk of infusion related reactions with IV Daratumumab the product monograph suggested a slow administration schedule that extends over several hours. This leads to a significant burden for the outpatients' treatment administration units and indirect costs to the patients such as time toxicity.

View Article and Find Full Text PDF

Biosynthetic mesh has become more popular for immediate breast cancer implant-based reconstruction as an alternative to acellular dermal matrix (ADM) for soft tissue support. This meta-analysis investigates the various biosynthetic options available as well as complications and outcomes. PubMed, MEDLINE, and Embase were systematically reviewed for studies investigating the following types of mesh, TIGR, Vicryl, PDO, TiLOOP, Durasorb, and Galaflex, and their associated outcomes.

View Article and Find Full Text PDF

Background: The Korean government is implementing policy to reduce medical costs and improve treatment related for human immunodeficiency virus (HIV) patients. The level of cost reduction and the benefits provided vary depending on how individuals with HIV utilize the system. This study aims to determine exact HIV prevalence by analyzing healthcare utilization patterns and examining differences in healthcare usage based on how individuals pay for their medical expenses.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!